Your PBM primer:

Senate Finance Committee hearing focuses on the mysteries of pharmacy benefit managers—their power and role in rising drug prices

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Pharmacy benefit managers, like climate change, germs and, possibly, God, are all around, and if we could clear a few hours, it would be good to learn enough about them to sustain a cocktail party conversation.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Claire Dietz
Claire Dietz
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
Claire Dietz
Claire Dietz
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login